VTVT
NASDAQ HealthcarevTv Therapeutics Inc. - Class A Common Stock
Biotechnology
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
๐ Market Data
| Price | $32.29 |
|---|---|
| Volume | 114,251 |
| Market Cap | 127.18M |
| Beta | 0.250 |
| RSI (14-Day) | 33.5 |
| 200-Day MA | $32.77 |
| 50-Day MA | $33.72 |
| 52-Week High | $44.00 |
| 52-Week Low | $14.00 |
| Forward P/E | -8.30 |
| Price / Book | 4.45 |
๐ฏ Investment Strategy Scores
VTVT scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (84/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find VTVT in your text
Paste any article, transcript, or post โ the tool will extract VTVT and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.